New radioactive drug targets Hard-to-Treat liver cancer
NCT ID NCT06852820
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a radioactive drug called 177Lu-PSMA-617 in 10 patients with PSMA-positive liver cancer that has spread. The goal is to see if the drug is safe and can shrink tumors. Patients must have already tried one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-PSMA-617 (a radioactive drug)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with PSMA-positive liver cancer that has spread.
- What could go wrong
- This is a very small pilot study (10 people) in early Phase 2, so results may not apply broadly. The drug is radioactive and may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?